Article
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
Antimicrobial agents and chemotherapy - 1 Nov 2001
Kaltenbach R F, Trainor G, Getman D, Harris G, Garber S, Cordova B, Bacheler L, Jeffrey S, Logue K, Cawood P, Klabe R, Diamond S, Davies M, Saye J, Jona J, Erickson-Viitanen S
Abstract excerpt
Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place because trough levels of free drug are inadequate to suppress preexisting resistant mutant variants and/or to inhibit de...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.